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E-mail address: yosef.yarden@weizmann.ac.il (Y. YThe EGF-receptor is frequently mutated in a large variety of tumors. Here we review the most fre-
quent mutations and conclude that they commonly enhance the intrinsic tyrosine kinase activity,
or they represent loss-of-function of suppressive regulatory domains. Interestingly, the constitutive
activity of mutant receptors translates to downstream pathways, which are subtly different from
those stimulated by the wild-type receptor. Cancer drugs intercepting EGFR signaling have already
entered clinical application. Both kinase inhibitors speciﬁc to EGFR, and monoclonal antibodies to
the receptor are described, along with experimental approaches targeting the HSP90 chaperone.
Deeper understanding of signaling pathways downstream to mutant receptors will likely improve
the outcome of current EGFR-targeted therapies, as well as help develop new drugs and
combinations.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction is achieved following a series of processes starting with the interac-The laboratory of Stanley Cohen discovered in 1980 that addition
of EGF to the culture medium of human epidermoid carcinoma
(A431) cells yields massive tyrosine phosphorylation, similarly to
cells infected with oncogenic viruses [1]. Although not known at
the time, it was speculated by Stanley Cohen and colleagues, that
the EGF-receptor (EGFR) and the observed kinase activity are pres-
ent in the samemolecule [2]. In the past 30 years we have learned a
great deal about the structure of growth factor receptors, their
intrinsic ligand recognition and kinase functions, and the cellular
outcomes of their activation. Upon their ligand-induced dimeriza-
tion, growth factor receptors initiate a vast array of cell signaling
pathways (Fig. 1), with profound effects on cell fate decisions such
as proliferation, cell lineage determination and differentiation,
migration and even cell death. Due to their importance, thesemech-
anisms evolved to be tightly regulated and robust. One of the best-
studied examples for such mechanisms is the EGFR family, also
called the ErbB family, which belongs to the super-family of recep-
tor tyrosine kinases (RTKs). These plasma membrane bound recep-
tors are mainly composed of an extracellular ligand-binding, and a
single trans-membrane domain, followed by an intracellular tyro-
sine kinase domain and a non-catalytic carboxyl terminal tail. This
conﬁguration allows extracellular signals to be relayed into the cell,
and to be interpreted in order to evoke a proper response: Activationchemical Societies. Published by E
arden).tion between the ligand and the ligand-binding domain of the
receptor. This binding induces a structural change which exposes
an otherwise tethered dimerization arm [3], leading to coupling of
two receptormolecules. Now, closer together in the correct orienta-
tion, the two kinase domains interact asymmetrically, while one ki-
nase acts as an activator and the second being activated [4]. The
activated kinase phosphorylates tyrosine residues located at the
receptor’s tail, which then act as docking sites for adaptormolecules
linking the receptor to its downstream signaling pathways (Fig. 1).
During evolution, the single nematode ErbB receptor, Let-23,
underwent two duplication events and subsequent incorporation
of further mutations, resulting in a family of four members in
mammals [5], which seem to be similar at the ﬁrst glance, but were
discovered to be profoundly different [6,7]. While ligand-binding
activates the kinase domain of EGFR/ErbB-1, as well as ErbB4,
ErbB-2 has no compatible ligand and is kept in a constitutively ac-
tive state [8]. On the other hand, ErbB-3 maintained its ligand-
binding capacity, but its kinase domain was mutated in a way that
it can only serve as a catalytically inactive activator of kinases in
the context of ErbB receptor heterodimers [9]. Owing to their sig-
niﬁcant similarities, these receptors may form homo- as well as
hetero-dimers, upon ligand-binding, thus assembling a spectrum
of activation options [10]. To further increase this system’s com-
plexity, ligands have evolved as well and are composed of a family
of eleven molecules, distinct with respect to their expression pat-
terns, binding speciﬁcities and afﬁnities to the ErbB receptors
[11–16]. Remarkably, each ligand is unique in multiple aspects,lsevier B.V. All rights reserved.
Fig. 1. Activation mechanisms and signaling pathways engaged by EGFR. In the absence of ligand, EGFR predominantly exists in a monomeric form, in which the kinase
domain is auto-inhibited by the carboxyl-terminal tail of the receptor. Ligand binding traps the extracellular domain of EGFR in a conformation poised to form receptor
dimers, which are mediated by mutual interactions of the dimerization loops. The resulting conformational change is relayed into the intracellular receptor portion, resulting
in the formation of an asymmetric dimer of kinase domains. In this asymmetric dimer, the C-lobe of the kinase domain of the ‘‘activator kinase” buttresses the kinase domain
N-lobe of the ‘‘receiver kinase”, resulting in catalytic activation of the latter. The receiver kinase then phosphorylates intracellular tyrosine residues of the activator kinase,
which cluster in the carboxyl-terminal tail. Phosphorylated tyrosine residues function as docking sites for signaling adaptors (e.g., Grb2), intracellular enzymes (e.g.,
PLCgamma) or transcription factors (e.g., STAT3). Thereby, activated EGFR couples to a myriad of intracellular signaling pathways mediating such diverse cellular responses as
cell lineage determination, proliferation, survival, or migration. The abbreviations used are: PI3K, phosphoinositide-3-kinase; PIP3, phosphatidylinositol-3,4,5-trisphosphate;
Akt, v-akt murine thymoma viral oncogene homolog; mTOR, mechanistic target of rapamycin; STAT, signal transducer and activator of transcription; PLCgamma,
phospholipase C gamma; IP3, inositol 1,4,5-triphosphate; DAG, diacylglycerol; PKC, protein kinase C; CAMK, calcium/calmodulin-dependent protein kinase; Grb2, growth
factor receptor-bound protein 2; Shc, Src homology 2 domain containing transforming protein; SOS, son of sevenless homolog; Ras, Ras viral oncogene homolog; Raf, Raf
murine viral oncogene homolog; MEK, mitogen-activated protein kinase kinase; ERK, mitogen-activated protein kinase (extracellular signal-regulated kinase).
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include cleavage of the precursor form, retention in the extracellu-
lar environment, preference for certain receptor heterodimers and
intracellular trafﬁcking.
Despite multiple regulatory mechanisms acting at the levels of
receptors and their downstream signaling pathways, which in-
crease the robustness of this system, the ErbB family represents a
major player in many types of malignancies. Robust as it is, every
complex system has its weaknesses, and the ErbB system is not dif-
ferent: cellular transformation can arise from receptor gene ampli-
ﬁcation or overexpression, which is thought to promote
dimerization by their shear numbers [17], or, conversely, by self-
production of ligands, which initiate signaling cascades in an auto-
crine manner [18]. A third option of short-circuiting this highly
regulated system is to bypass some of its inherent control. In this
review, we will focus on the regulatory elements imposed by the
molecular structure of EGFR, along with the question how cancer
mutated its way to overcome these regulatory elements. In addi-
tion, we will highlight therapeutic approaches aiming to overcome
aberrant modes of EGFR activation.
2. EGFR mutations are not random
Mutant forms of EGFR have been found in several human tumor
types. The aberrant forms characterize a limited set of tumors, but
their causes and reasons for cell lineage speciﬁcity remain un-known. In addition, these alterations are not evenly dispersed
along the EGFR gene, but rather cluster in speciﬁc areas, leading
to the assumption that mutational ‘‘hot spots” entail elements of
special functional or regulatory importance (Fig. 2).
2.1. The ectodomain hotspot
A primary safeguard mechanism, which prevents premature
receptor dimerization and subsequent activation, is the ligand-
binding domain. Formation of stable receptor dimers can only be
achieved upon ligand-binding, followed by a constructive dimer
formation. The viral EGFR homologue, v-ErbB, which induces eryth-
roblastosis in birds and contributed its name to the ErbB family,
lacks the whole extracellular domain. With the dimerization con-
strains removed, this viral protein was found to exist primarily in
dimers, leading to constitutive kinase activation and subsequent
oncogenicity [19]. Interestingly, similar deletion mutants have
been discovered in human gliomas (Table 1 and Fig. 2). One of these
mutant forms, EGFR variant III (EGFRvIII), was found to lack a large
part of the extracellular portion, including components of the li-
gand-binding domain [20]. Indeed, although ligand insensitive, this
mutated form was found to be constitutively dimerized and highly
tumorigenic [21], resembling the activity of its viral counterpart.
Additionally, apart from deletions, this ectodomain’s hot spot at-
tracts point mutations, most of which were reported to be onco-
genic [22], presumably by promoting receptor dimerization.
Fig. 2. Receptor aberrations cluster in functionally relevant hotspots of EGFR. Structural constraints impose ligand binding for receptor activation. Brain tumors such as
glioblastoma multiforme (GBM) circumvent this requirement by deletions or point mutations in the ligand-binding domain (e.g., EGFRvIII) of EGFR, which promote receptor
dimerization and activation. Alternately, GBMs may enhance the EGFR catalytic activity through duplications of its kinase domain, as well as by deletions in the carboxyl-
terminal tail, which may otherwise execute an auto-inhibitory role on the kinase activity. Conversely, non-small cell lung cancers (NSCLC) often exhibit prototypical point
mutations or small insertions/deletions in kinase domain regions regulating the basal catalytic activity of EGFR.
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Unlike other RTKs, which must undergo phosphorylation within
the activation loop of the kinase domain in order to achieve the
catalytically active conformation, EGFR does not require this mod-
iﬁcation [23]. Here, the activity of the kinase domain is controlled
by conformational changes induced by dimer formation and possi-
bly by the distal carboxyl terminus. Following the rationale of reg-
ulation-bypassing, non-small cell lung cancer (NSCLC) and other
tumors harbor point mutations, small deletions or insertions of
the EGFR kinase domain [24–26], rendering this domain constitu-
tively active [27] even in the absence of upstream events such as
ligand-binding or dimerization.
2.3. The C-tail hotspot
In addition to activation by means of kinase mutations, a dele-
tion mutant found in gliomas, named EGFRvIV, lacks either two or
three exons in its carboxyl tail, downstream to the kinase domain
[20,28], while keeping most of the auto-phosphorylation tyrosineTable 1
Common EGFR mutations.
Cancer type Name Domain affected Mutation type
GBM EGFRvI Extracellular Deletion
EGFRvII Extracellular Deletion
EGFRvIIIa Extracellular Deletion
EGFRvIV Carboxyl tail Deletion
EGFRvV Carboxyl tail Deletion
EGFR TDM Kinase Duplication
NSCLC 746-759b Kinase Deletion
L858Rc Kinase – activation loop Point mutatio
G719Scc Kinase – nucleotide-binding loop Point mutatio
T790M Kinase Point mutatio
D770InsNPG Kinase Insertion
ND, Not determined.
a EGFRvIII has been identiﬁed in lung, breast, ovarian and other tumors [35,36].
b Various deletions within the indicated range have been reported.
c G719S and L858R are representative point-mutations in exons 18 and 21, respectiveresidues intact. According to structural [29,30] and computational
analyses, the deleted segment likely plays an essential role in ki-
nase auto-regulation by folding over the kinase domain, implying
that its removal will result in constitutive kinase activity [31].
Additionally, the notion of a regulatory role of the carboxyl tail
may explain the constitutive activation of a kinase-duplication mu-
tant, in which only one kinase is predicted to be inhibited by the
tail, while the other may represent an active form [32].
3. Pathologic aspects of the common oncogenic mutants of
EGFR (see Table 1)
3.1. EGFRvIII in brain and other tumors
Since its discovery in 1990 [33], EGFRvIII has been a subject of
thorough investigation, which is justiﬁed by its relative abundance
in brain tumors, and frequent detection in other malignancies,
including lung, breast and ovarian cancers [20,34–36]. As men-
tioned above, by deletion of a segment of the ligand-binding do-
main, EGFRvIII bypasses the need of ligand. This deletion spansBiochemical traits Reference
ND [34]
ND [28,104]
Basal dimer formation, basal kinase activity [20,28,34,38]
Predicted basal kinase activity [20,28,30,31]
ND [20,28]
Basal kinase activity, escapes down regulation [28,32]
Basal kinase activity [105,106]
n Basal kinase activity [105,106]
n Basal kinase activity [105,106]
n Confers reversible TKI resistance, increases basal activity [76]
Basal kinase activity, confers reversible TKI resistance [106]
ly.
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at the fusion junction. Interestingly, EGFRvIII is commonly diag-
nosed in tumors that overexpress the wild-type form of EGFR, sug-
gesting that receptor overexpression precedes deletion of exons 2–
7 [28,33]. While this mutant cannot bind ligands, it resides at the
cell membrane [37], often within receptor dimers [38] that display
constitutive basal activity. EGFRvIII has been shown to be trans-
forming both in vitro and in vivo, as it confers anchorage-indepen-
dent growth of cultured cells and promotes tumor formation in
athymic mice [39]. Curiously, the oncogenic capacity of EGFRvIII
may propagate into non-expressing cells by means of cell-to-cell
transfer of membrane-derived microvesicles [40].
3.2. Kinase mutations in NSCLC
Mutations in the EGFR kinase domain are often diagnosed in
NSCLC, particularly in tumors occurring in individuals of Eastern
Asian origin, females, never smokers, and in adenocarcinomas with
bronchioloalveolar histological features [41,42]. These mutations
spread along the kinase-coding regions (exons 18–21), and they
all seem to catalytically stimulate the basal kinase activity,
although by different means. Exons 18 and 19 encode for the phos-
phate-binding loop, also termed the P-loop. While exon 18 displays
point mutations, mainly G719X (X indicates A, C, S or D), which
represent about 4% of EGFR mutations in NSCLC, exon 19 is usually
affected by deletions, which represent 44% of kinase domain muta-
tions. Exon 20, which encodes for the a-C helix, harbors relatively
rare (4%) insertion mutations, whereas exon 21, encoding the acti-
vation loop (A loop), encompasses point mutations that account for
41% of mutations, including the prototypical L858R mutation [43].
All these mutations are believed to destabilize the inactive kinase
conformation, hence driving it to a more active state [44]. Notably,
in contrast to EGFRvIII, kinase-mutated EGF-receptors retain their
responsiveness to growth factor ligands [45], which further en-
hance catalytic activity, relatively to wild-type EGFR [24].4. Novel signal transduction features of EGFR mutants
Even though the mutated EGF-receptors that are frequently
found in tumors were proven to be catalytically active and tumor-
igenic, their activation proﬁle is essentially different than that of
the ligand-activated wild-type receptor. Usually, EGFR tyrosine
phosphorylation status is signiﬁcantly lower in mutated receptors
compared to ligand-activated wild-type receptors, yet clearly ex-
ceeds its unstimulated state. Apparently, this basal but chronic
activity relays signals in a profoundly different manner than the
well-characterized canonical signal-transduction machinery.
4.1. The case of EGFRvIII
An example for such discrepancy between wild-type and mu-
tant signaling potentials is EGFRvIII activation: while the wild-type
EGFR activates several signaling pathways upon ligand-binding
(Fig. 1), the constitutively-dimerized mutant preferentially acti-
vates the Phosphatidylinositol 3-Kinase (PI3K) pathway over other
pathways such as the mitogen-activated protein kinase (MAPK)
pathway [46–48]. Indeed, EGFRvIII instigates the expression of
only a subset of genes induced by the ligand-stimulated wild-type
EGFR [49].
4.2. Mutant EGFRs escape negative regulation
Another important feature of the relatively high basal signaling
of EGFR mutants is their ability to evade negative, activation-
dependent regulation. The customary EGFR signal attenuator isthe ubiquitin-ligase CBL, which is recruited to a speciﬁc phosphor-
ylated tyrosine residue located at the receptor’s tail (Y1045). When
bound, CBL attaches mono- and di-ubiquitin moieties to multiple
lysine residues of EGFR, thus tagging the receptor for lysosomal
degradation, and thereby deﬁning the temporal window of signal-
ing of activated EGFR. Apparently, in some cases, including the
NSCLC single (L858R) and double mutant (L858R/T790M), basal
EGFR activation results in differential phosphorylation of tail tyro-
sine residues [22,50–52], allowing uncontrolled downstream sig-
naling. This aberrant activation pattern is achieved by
phosphorylation of tyrosine residues responsible for propagating
the signal downstream, while Y1045 is kept at a weakly phosphor-
ylated state, thus allowing the mutated receptors to signal ‘‘under
the radar” of receptor attenuating mechanisms.5. Cancer therapies targeting aberrant forms of EGFR
Due to the frequent involvement of the ErbB family in cancer,
intercepting its members became a natural goal of the targeted
therapy approach. In contrast to chemotherapy, which is highly
toxic and often results in adverse clinical effects, targeted therapy
aims speciﬁcally at the relevant renegade protein. Although tumors
harbor multiple genetic abnormalities, according to the ‘‘oncogene
addiction” theory, their tumorigenic drive may be attributed to a
single pathway, to which the tumor became ‘‘addicted” [53]. In-
deed, in many cases, when this pathway is pharmacologically
blocked, cancer cells die, leading to tumor regression. A related
theory, termed the ‘‘oncogenic shock”, proposes that short-lived
pro-survival signals are depleted due to treatment, leaving the cell
with long-lived pro-apoptotic elements that drive cell death [54].
Regardless of the mechanism, RTK targeting has been proven ben-
eﬁcial across a wide spectrum of malignancies. Accordingly, ErbB
proteins and other RTKs are currently directly targeted using two
distinct strategies (Fig. 3).
5.1. Tyrosine kinase inhibitors
One of the outcomes of the pursuit for EGFR inhibiting agents
was the development of small molecules that bind to the ATP-
binding pocket of the kinase domain, thereby inhibiting its enzy-
matic activity. These tyrosine kinase inhibitors (TKIs) mimic ATP,
which serves as phosphate source for the phosphorylation process
[55]. TKIs may bind either reversibly or irreversibly, and their spec-
iﬁcity can be designed to target EGFR alone, several ErbB family
members, or even other tyrosine kinases as well. Two such mole-
cules, Erlotinib (OSI-774, Tarceva) and Geﬁtinib (ZD 1839, Ires-
sa) are reversible EGFR-speciﬁc TKIs, which are already in
clinical use for treatment of NSCLC and pancreatic adenocarcino-
mas [56–59]. A third approved compound, lapatinib/Tykerb
inhibits both EGFR and its closest kin, HER2/ErbB-2, and is success-
fully used in patients with HER2-overexpressing metastatic breast
cancer [60,61].
5.2. Monoclonal anti-receptor antibodies
The ﬁrst broadly successful monoclonal antibody (mAb) to tar-
get the ErbB system in human malignancies was trastuzumab, a
humanized mAb targeting ErbB-2/HER2, a receptor frequently over
expressed in breast cancer [62]. Trastuzumab (Herceptin), is
widely used now as a common treatment for patients with ErbB-
2 overexpressing breast cancer [63–65]. EGFR’s extracellular do-
main is similarly targeted using speciﬁc antibodies, with the aim
of inhibiting ligand-binding and accelerating receptor down-regu-
lation, following antibody-directed clustering and aggregation
[66]. In addition, recruitment of the patient’s immune system to
Fig. 3. Therapies targeting EGFR signaling. Oncogenic aberrations of the EGFR extracellular domain may result in exposure of novel epitopes not displayed by the wild-type
receptor. In context of the EGFRvIII deletion, monoclonal antibodies targeting such epitopes (e.g., mAb 806) have already demonstrated clinical activity. Monoclonal
antibodies targeting the wild-type EGFR have demonstrated substantial activity in patients with colorectal cancer, head and neck cancer, and non-small cell lung cancer
(NSCLC). Tyrosine kinase inhibitors (TKIs) represent another class of anti-EGFR agents. These small ATP-mimetics readily penetrate into the cell, with geﬁtinib and erlotinib
binding to the kinase domain in its active conformation, and inhibiting transfer of phosphate moieties. Patients with NSCLC harboring mutations in the EGFR kinase domain
are particularly sensitive to TKIs (kinase marked in red). Erlotinib is approved also for patients with pancreatic cancer. Another, non-direct strategy entails HSP90 inhibition;
mutated and activated EGF-receptors have been shown to serve as HSP90 clients, demonstrating signiﬁcantly reduced activity upon its inhibition by benzoquinoid
ansamycins, such as geldanamycin derivatives.
G. Pines et al. / FEBS Letters 584 (2010) 2699–2706 2703the cancer cells, via the antibody’s Fc region, to promote antibody-
dependent cell-mediated cytotoxicity, is considered another
advantage of this approach [67]. Cetuximab (C225, Erbitux) is a
humanized mouse antibody that is approved for treatment of
two clinical indications: patients with metastatic colorectal cancer
(harboring wild-type KRAS, see below), or patients with advanced
or recurrent head and neck cancer. The antibody has also shown
some activity in NSCLC [68]. Panitumumab (Vectibix) is a fully
human EGFR antibody approved for treatment of advanced colo-
rectal cancers that express wild-type KRAS and progressed during
or after previous lines of therapy [69,70].
Because EGFRvIII exhibits a novel epitope at its extracellular do-
main, which is exclusive to cancer cells, antibodies speciﬁcally tar-
geting this mutated form were generated and showed encouraging
initial results in clinical trials [71]. Other therapies also utilize the
epitope differences between EGFRvIII and its wild-type counter-
part. Active immunization with peptides based on the fusion junc-
tion of EGFRvIII was proven effective in animal models [72].
Additionally, a re-targeted oncolytic measles strain, that speciﬁ-
cally identiﬁes EGFRvIII, exhibited host cell speciﬁcity both
in vitro and in animals, adding virus targeted therapy to the battery
of future potential therapies [73].
5.3. Games of cat and mouse – EGFR secondary mutations
A unique opportunity to grasp the mutational micro-evolution
of cancer progression has arisen through the treatment of NSCLC
patients with geﬁtinib or erlotinib. Clinical trials have shown that
only a relatively small portion of patients responded to the TKI
treatment, but with impressive clinical improvement [24]. Further
studies discovered that TKI responsiveness was dependent onpoint mutations or small deletions within the kinase domain.
These mutations, while activating the kinase, also conferred sensi-
tivity to treatment [52,74]. However, soon afterward, many of the
responsive tumors relapsed under ongoing TKI treatment.
Sequencing of the kinase domain from these tumors revealed a sec-
ondary mutation (T790M) that not only increases kinase activity,
but grants TKI resistance as well [75,76]. Later, this phenomenon
was repeated in mouse models establishing it as a secondary, resis-
tance providing mutation [76], although it has been identiﬁed as a
germ-line mutation in families with inherited cancer susceptibility
as well [77]. This is an outstanding demonstration of cancer mech-
anisms relentlessly seeking for active signaling despite external
perturbations.
5.4. Mutations downstream to EGFR
Apart from additional mutations that evolve to rescue EGFR
activity and tumor progression, as seen in NSCLC, further muta-
tions may preexist or appear in other components of signaling
pathways, thus shifting the oncogenic addiction downstream,
and rendering EGFR targeting insufﬁcient. In glioblastomas, only
a fraction of patients respond to EGFR TKI treatment. Thorough
analysis revealed that some non-responsive tumors, although
expressing the mutated EGFRvIII, displayed decreased expression
of PTEN (phosphatase and tensin homolog) [78]. PTEN is a tumor
suppressor (Fig. 1) that reverses the action of PI3K, transforming
the second messenger PIP3, which is responsible for AKT activa-
tion, back to PIP2, therefore attenuating this signaling cascade. Tu-
mors that lost PTEN expression often exhibit a constitutively active
PI3K pathway, regardless of the status of EGFR. Indeed, reintroduc-
tion of PTEN into glioblastoma cells in vitro re-sensitized them to
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colorectal cancer (CRC) as well, in which additionally to PTEN dele-
tion, PI3K activating mutations have been reported [79]. Additional
downstream mutated proteins that confer resistance to EGFR-tar-
geted therapy in colorectal cancer are KRAS and BRAF (see
Fig. 1). Although EGFR is ubiquitously expressed in CRC, tests have
shown that only patients expressing the wild-type KRAS and BRAF,
which are major mediators of the MAPK pathway, will beneﬁt from
anti-EGFR treatment [80,81]. Moreover, several reports concluded
that occurrence of either EGFR or KRAS mutations are mutually
exclusive in NSCLC [82], highlighting the apparent functional
redundancy of these mutations.
5.5. The least explored route – recruitment of heat shock protein (HSP)
90
HSP90 is a molecular chaperone that facilitates proper folding
of speciﬁc client proteins in an ATP-dependent manner [83], and
has a signiﬁcant role in buffering genetic variation, contributing
to evolutionary processes [84]. However, HSP90 also stabilizes vir-
al kinases and mutated oncoproteins, such as v-SRC [85] and Bcr-
Abl [86], revealing an inevitable darker side. While the constitu-
tively active ErbB-2/HER2 is yet another HSP90 client [87], mutant
forms of EGFR, probably due to their constitutively-active kinases,
are dependent on the chaperoning function of HSP90 through di-
rect interaction, which warrants their stability [88–91]. Indeed
HSP90 inhibition, using benzoquinoid ansamycins such as geldana-
mycin, reduces mutant EGFR levels and activity, suggesting an
alternative EGFR inhibition strategy [92].6. Concluding remarks
Evolution is usually referred to natural selection of species, with
survival of the ﬁttest to a changing environment. However, the
same concept applies to cancer progression [93,94]: a tumor is
composed of heterogeneous sub-clones, with each harboring
slightly different sets of mutations [95]. Environmental stress, such
as hypoxia, immune mediators and therapeutic interventions, se-
lects the ﬁttest clones for survival, thus pushing the tumor further
to aggressiveness, and to ﬁnding new solutions for new pressures,
such as in the case of secondary NSCLC mutations. Recently, a new
generations of irreversible TKIs have been shown to exhibit activity
against the secondary T790Mmutation [96], thus raising the ‘‘arms
race” to a new level. Time will tell whether new, tertiary resistant
mutations will emerge, or whether this will drive tumors into
switching to other kinases in their thrive for growth signals, such
as ErbB-3 and MET, the receptor for the hepatocyte growth factor
[97,98].
The discovery of the ﬁrst oncogenes and tumor-suppressors
helped in understanding the nature of cancer [99]. The acquisition
of gain-of-function and loss-of-function mutations seems to simi-
larly apply to the smaller scale of single proteins, such as EGFR:
gain-of-function mutations affect the kinase domain, whereas
regulatory safe-guards embedded within the EGFR, such as the
ligand-binding domain and the carboxyl tail, are the targets of
loss-of-function mutations. Interestingly, speciﬁc cancer types
choose different strategies.
Drug development, in its constant pursuit for maximizing clin-
ical efﬁcacy, while minimizing toxicity, led to a major effort con-
centrating on EGFR-targeted therapies. However, according to the
lessons learnt from RAS mutations and PTEN deletions, in order
to predict which patient will beneﬁt from such treatments, the
whole genomic and proteomic status of a tumor should be mapped
and analyzed. With deep sequencing, microarray technology and
high throughput proteomics, such an ambitious task may be plau-sible sooner than expected. Patient-speciﬁc drug combinations will
have to consider not only the aberrant gene itself, but also common
compensatory pathways to be simultaneously targeted, such as
MET, AKT and ErbB-3, in the case of EGFR. Moreover, a third circle
of inhibitors may be required, such as modiﬁers of the tumor’s
stroma [100], blockers of angiogenesis [101], and HSP90 inhibitors.
In lung tumors harboring mutant forms of EGFR, speciﬁc TKIs have
already demonstrated superior efﬁcacy and tolerability compared
to conventional cytotoxic agents [102,103]. In the foreseeable fu-
ture, similar approaches along with rationally designed combina-
tions of targeted therapies, will hopefully achieve the goal also in
brain and other tumors expressing mutant forms of EGFR.
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